09 Jul How Proper CBD Oil Administration Supports Sleep and Ease in Neurological Wellness
Cannabis/CBD Notice: Cannabis products are not FDA monitored or approved. Discuss your use of medicinal cannabis or CBD products with your healthcare provider before use. Dosing is variable and products may interfere with other medications, stimulants and alcohol. Do not use cannabis or CBD products if you are pregnant, nursing, or may become pregnant. Do not use cannabis products when driving or operating difficult or dangerous machinery. Keep out of reach of children. Children and pets should not be exposed to cannabis or CBD products. See below for full disclaimer.
Living with a neurological condition brings daily challenges that go beyond physical symptoms like tremors or muscle stiffness. Many people also struggle with persistent fatigue, poor sleep, and chronic discomfort. While standard medical treatments focus on movement and motor function, addressing sleep quality and mental calm is equally important for maintaining quality of life.
Plant-based approaches are gaining increasing attention in healthcare discussions. Cannabidiol (CBD) offers a way to support calmness and relaxation without intoxicating effects. For those interested in exploring this option, regulated medical platforms such as Releaf provide expert guidance, personalised dosing advice, and third-party tested products.
[caption id="attachment_74881" align="aligncenter" width="500"]
Photo by Kindel Media[/caption]
Dr. Edward Liu[/caption]
MedicalResearch.com Interview with:
Edward Liu, MD
Geisinger College of Health Sciences
Scranton, PA 18509
Medicalresearch.com: What is the background for this study?
Response: Prescription drugs have high levels of uniformity that plant-based products cannot achieve. Given the liberalization of state-laws regarding medical marijuana1 over the past three-decades and increasing evidence of evidence of cannabis for conditions like chronic pain,2 we were interested in the use of the prescription formulation of delta(Δ)9-tetrahydrocannabinol (THC). A prior pharmacoepidemiology report found that prescription THC (dronabinol) to Medicaid patients decreased from 2016 to 2020. There were also pronounced state-level disparities in prescribing with a 130-fold difference when correcting for population between the highest and lowest states.
There was no research on this topic among Medicare patients. To address this gap, we obtained prescription numbers nationally and at a state level from 2014 to 2019 for Medicare Part D patients.
Source: IMAGE[/caption]
Dr. Kruger[/caption]
MedicalResearch.com: What is the background for this study?
[caption id="attachment_72137" align="alignleft" width="100"]
Dr. Felicione[/caption]
Response: Alcohol consumption, especially heavy alcohol consumption, is associated with many health risks and nearly 200 different health conditions and diseases. Reducing alcohol consumption reduces the risks and harms from alcohol. Previous research has demonstrated that people have reduced their alcohol consumption when they have access to cannabis. Cannabis beverages have emerged in States where cannabis is legal for adult or medical use.
Dr. Dunbar[/caption]
MedicalResearch.com Interview with:
Michael S. Dunbar, PhD